BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Business

  Proteonomix, Inc. (PROT) Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency

  June 7, 2010

   · 

  2 min read
• Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action

  June 7, 2010

   · 

  3 min read
• Pharm Country

  CureMark Presents at the Rodman & Renshaw Global Healthcare Conference

  June 7, 2010

   · 

  2 min read
• Drug Development

  ImmunoGen, Inc. Announces Presentation of Clinical Data for Trastuzumab-DM1 at American Society of Clinical Oncology Annual Meeting

  June 7, 2010

   · 

  1 min read
• Drug Development

  Celldex Therapeutics, Inc. Release: Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual American Society of Clinical Oncology Meeting

  June 7, 2010

   · 

  1 min read
• Drug Development

  Incyte Corporation Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented at American Society of Clinical Oncology

  June 7, 2010

   · 

  1 min read
• Drug Development

  Progenics Pharmaceuticals, Inc. Phase 1 PSMA ADC Study Presented in New “Trials in Progress” Poster Session at American Society of Clinical Oncology Annual Meeting

  June 7, 2010

   · 

  1 min read
• Drug Development

  Plexxikon Inc. Release: PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported

  June 7, 2010

   · 

  1 min read
• Drug Development

  The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

  June 7, 2010

   · 

  1 min read
• Drug Development

  AVEO Pharmaceuticals, Inc. Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile

  June 7, 2010

   · 

  1 min read